Table 1.
Models | Changes | Interventions | Refs. |
---|---|---|---|
Rat/EP | Occludin redistribution (IHC) | Glibenclamide | Simard et al. [62] |
Rat/BI | Occludin/ZO-1 ↓ (WB) 48h | HIF-1α, MMPs, aquaporin-4 | Wang et al. [63] |
Rat/EP | Occludin/ZO-1 ↓ (WB/IHC) 24h | c-Jun N-terminal kinase inhibition | Chen et al. [64] |
Mice/EP | Claudin-5/ZO-1/JAM-A/VE-cadherin ↓ (WB) 24h | Isoflurane | Altay et al. [65] |
Rat/EP | Occludin/ZO-1/claudin-5 ↓ (WB) 24h | Melatonin | Chen et al. [66] |
Rat/EP | Occludin/ZO-1 ↓, claudin-1/5 ↔ (WB, IHC) 0.5 – 168h | None | Li et al. [7] |
Rat/EP | Occludin/ZO-1/claudin-5/VE-cadherin ↓ (WB, IHC) 24h | Norrin/frizzled-4 | Chen et al. [67] |
Mice/EP | ZO-1/VE-cadherin ↓ (WB, IHC) 24 h | Thrombomodulin | Xu et al. [68] |
Rat/EP | ZO-1 ↓ (WB) 24h | Progranulin | Zhou et al. [69] |
Rat/BI | ZO-1 ↓ (WB) 24h | Fisetin (flavonoid) | Zhou et al. [70] |
Rat/BI | Claudin-5/occludin ↓ (WB) 24h | PARP inhibition | Chen et al. [71] |
Mice/EP | ZO-1 ↓ (WB) 24 h | Tenascin-C | Fujimoto et al. [72] |
Rat/EP | Claudin-5/occludin ↓ (WB) 24h | Ethyl pyruvate | Fang et al. [73] |
Rat/EP | Claudin-5/occludin ↓ (WB) 24h | Valproic acid | Ying et al. [74] |
Rat/BI | Occludin/ZO-1 ↓ | Matrine (alkaloid) | Liu et al. [75] |
Mice/EP | Occludin/ZO-1/claudin-5 ↓ (WB) 48h | Apolipoprotein E | Pang et al. [76] |
Mice/EP | Occludin/ZO-1 ↓ (WB) 24h | Curcumin | Yuan et al. [77] |
Rat/EP | Claudin-5/ZO-1 ↓ (WB) 24h | Eph receptor-A4/Fasudil (ROCK inhibition) | Fan et al. [78] |
Rat/EP | ZO-1 ↓ (IHC) 24 h | Tropomyosin-related kinase receptor B activation | Qi et al. [59] |
Rat/EP | Occludin/Claudin-5 ↓(WB) 24h | Nrg1 isoform β1 | Qian et al. [79] |
↓: decrease; ↔: no change; EP: endovascular perforation; BI: blood injection; WB: western blot; IHC: immunohistochemistry; ROCK: RhoA kinase; HIF-1a: hypoxia-inducible factor-1a; MMPs: matrix metalloproteinases; PARP: Poly (ADP-ribose) polymerase.